US20030220395A1 - Treatment of ocular hypertension and glaucoma - Google Patents

Treatment of ocular hypertension and glaucoma Download PDF

Info

Publication number
US20030220395A1
US20030220395A1 US10/385,621 US38562103A US2003220395A1 US 20030220395 A1 US20030220395 A1 US 20030220395A1 US 38562103 A US38562103 A US 38562103A US 2003220395 A1 US2003220395 A1 US 2003220395A1
Authority
US
United States
Prior art keywords
dose
latanoprost
oxo
eye
isopropyl ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/385,621
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Priority to US10/385,621 priority Critical patent/US20030220395A1/en
Publication of US20030220395A1 publication Critical patent/US20030220395A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Definitions

  • latanoprost is now sold commercially as an IOP (intraocular pressure) reducing eye drop.
  • the clinical dosage is 1.5 ⁇ g per dose as an eye drop, once a day. This is the U.S. FDA approved dosage.
  • the provided liquid composition product can contain 0.005% latanoprost used at a dosage of one drop, or about 30 ⁇ l, providing 1.5 ⁇ g per dose.
  • Latanoprost is named by Stjernschantz as 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF 2 ⁇ isopropyl ester.
  • the above noted patent describes a wide potential dosage range as therapeutically active.
  • the composition contains about 0.1-30 ⁇ g, especially 1-10 ⁇ g, per application of the active substance . . . ”
  • the lowest dosage used in the '128 patent for any test compound for evaluating IOP reduction in humans or monkeys is 1.0 ⁇ g per eye.
  • the tested dosage in healthy human volunteers is 5 ⁇ g per eye and is 3 ⁇ g in the monkey eye.
  • Latanoprost is tested in the '128 patent at a dosage of 1.0 ⁇ g per eye in healthy human volunteers and at a dosage of 10.4 ⁇ g in the monkey eye.
  • Latanoprost at its clinical concentration can cause pigmentation of the iris, a mild IOP spike and/or mild hyperemia.
  • 15-keto latanoprost can be used in an unusually low dosage for reduction of IOP.
  • Another embodiment of the present invention is the use of 15-keto latanoprost at a dosage up to about the clinical dosage of latanoprost.
  • 15-keto latanoprost does not cause iridic pigmentation, an initial IOP spike nor any hyperemia at the dosages described herein.
  • Still another embodiment of the present invention is the use of 15-keto latanoprost for maintaining IOP reduction over an extended time following an initial rapid IOP reduction bought about by another IOP reducing agent, such as latanoprost.
  • the embodiments of the present invention involve treatment of glaucoma where IOP reduction is needed and the lowering of IOP for purposes other than treatment of glaucoma.
  • This application describes other 15-keto prostaglandins useable at low dosages for treating ocular hypertension and glaucoma.
  • FIGS. 1 and 2 set forth the results of Example 1 comparing the employment of a dose of 0.175 ⁇ g latanoprost (FIG. 1) and the same dose of 15-keto latanoprost (FIG. 2) in the monkey eye.
  • FIG. 3 is a graph depicting a comparison of the results for the active ingredients of Example 1 without the controls, as depicted in FIGS. 1 and 2.
  • FIG. 4 depicts the results of Example 2 where an additional instillation of a small amount of latanoprost or 15-keto lantanoprost is administered 12 hours after instillation of a clinical dose of latanoprost in the monkey eye.
  • the present invention relates to the employment of varying, including small, ocular dosages of 15-keto latanoprost, and related 15-keto compounds, as an IOP reducing agent, administered topically to the eye in the treatment of glaucoma or ocular hypertension.
  • the active agent is administered as a topically applied ocular composition, most usually in the form of a liquid eye drop.
  • the dose of 15-keto latanoprost is selected so that any side effects caused by the ocular application of prostaglandin analogs, including those which contain a ring such as latanoprost, are substantially completely eliminated.
  • the effective dose exemplified herein can be as low as about one-tenth the clinical dose of latanoprost.
  • the ophthalmic vehicle employed in the practice of the present invention is that now know in the art for IOP reducing agents, such as the a-fore-mentioned latanoprost and Rescula®, the latter which has an extended omega chain providing a docosanoid classification. Additional information on ophthalmic vehicles is found in the patent noted in the background section of this patent application. Although 15-keto latanoprost is an isopropyl ester, it is contemplated that the free acid as well as pharmaceutically acceptable salts, ethers and other esters are potentially useful in the practice of the present invention, such as those described in the above-noted patent.
  • the clinical dose for latanoprost is about 1.5 ⁇ g per eye. At one-tenth the clinical dose, latanoprost is essentially inactive. Quite surprisingly, 15-keto latanoprost is an effective IOP reducing agent when used at about one tenth the clinical dose of latanoprost. It is contemplated in one embodiment of the present invention that the dosage range for 15-keto latanoprost as a topically applied ocular IOP reducing agent is about 0.100 to 0.750 ⁇ g/eye, preferably about 0.125 to 0.250 ⁇ g/eye, more preferably about 0.150 to 0.175 ⁇ g/eye.
  • the dosage range for 15-keto latanoprost as a topically applied ocular IOP reducing agent is about 0.050 to below 5.0 ⁇ g/eye, or about 0.10 to 4.5 ⁇ g/eye, or about 0.50 to 2.5 ⁇ g/eye, or about 1.0 to 2.0 ⁇ g/eye.
  • This Example is an IOP test using the monkey eye in which about one tenth the clinical dose of latanoprost is compared in IOP reduction with the same dose of 15-keto latanoprost.
  • the solution containing 15-keto-latanoprost or latanoprost at 0.0005% was prepared with the following vehicle.
  • Composition of the vehicle 1) (/mL): NaCl (4.1 mg), NaH 2 PO 4 -H 2 O (4.6 mg), Na 2 HPO 4 -2H 2 O (5.94 mg), Benzalkonium Chloride (0.2 mg) and water for injection
  • the intraocular pressure in each group before the instillation was as follows (in mmHg, mean ⁇ S.E.): the group receiving 15-keto-latanoprost; the right eye: 16.6 ⁇ 0.5, the left eye: 16.6 ⁇ 0.2, the group receiving latanoprost; the right eye: 15.8 ⁇ 0.7, the left eye: 17.0 ⁇ 0.3. There were no statistically significant differences between the values of the intraocular pressure before the instillation (Student's t-test).
  • the animals were systemically anesthetized by an intramuscular injection of 5 mg/kg of ketamine hydrochloride (Ketalar®50, Sankyo Co., Ltd.), and the interior segment of both eyes was anesthetized by a instillation of 0.4% oxybuprocaine hydrochloride (Benoxil® 0.4% solution, Santen Pharmaceutical Co., Ltd.).
  • the animals were fixed in a sitting position, and the intraocular pressure was measured by use of an applanation pneumatonograph (Alcon Japan Ltd.) before, and 2, 4, 8, 12 and 24 hours after the instillation.
  • the animals were kept in cages excepting the time of measurement of the intraocular pressure.
  • This Example illustrates the employment of a low dose of 15-keto latanoprost for maintaining a low IOP level following single administration of another IOP reducing agent for obtaining a rapid drop in IOP.
  • the animals were treated by the instillation with latanoprost at the clinical concentration alone, or additional instillation of a small amount of latanoprost or 15-keto-latanoprost 12 hours after instillation of latanoprost when the IOP showed the maximum reduction after instillation of latanoprost.
  • the changes of IOP in 3 different treatment groups were compared to investigate the significance of the presence of 15-keto acid of latanoprost, a 13,14-dihydro-15-keto type metabolite, in maintaining the IOP lowering effect observed after instillation of latanoprost.
  • 0.0005% and 0.005% latanoprost eye drops and 0.0005% 15-keto-latanoprost eye drops were prepared with a vehicle consisting of the following composition.
  • the composition of the vehicles in 1 mL was as follows: sodium chloride (4.1 mg), sodium hydrogenphosphate-1H 2 O (4.6 mg), disodium hydrogenphosphate-2H 2 O (5.94 mg), benzalkonium chloride (0.200 mg) and water for injection (1 mL).
  • FIG. 4 shows, when 0.005% latanoprost alone was instilled into the eye of monkeys, IOP decreased with time at 4, 8 and 12 hours after instillation. The IOP returned with time toward the predosing levels at 16 and 20 hours after instillation of 0.005% latanoprost. IOP returned toward the predosing levels at 24 hours after instillation.
  • the IOP was maintained at significantly low levels when 0.0005% 15-keto-latanoprost was additionally instilled at 12 hours after instillation of 0.005% latanoprost as compared with that when 0.005% latanoprost alone was instilled, or that when 0.0005% latanoprost was additionally instilled 12 hours after instillation of 0.005% latanoprost.
  • 15-keto prostaglandins which should be useful in the practice of the present invention are 15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF 2 ⁇ and 13,14-dihydro-15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF 2 ⁇ isopropyl esters.
  • the corresponding pharmaceutically acceptable salts, ethers, other esters and amides should be useful in the practice of the present invention. See U.S. Pat. No. 5,510,383 for the corresponding 15-OH compound.
  • the clinical (once a day) dosage (FDA approved dosage) for 16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF 2 ⁇ isopropyl ester is one drop of a 0.004% solution. Drop size can range from about 20 to 50 ⁇ l, typically about 30 to 35 ⁇ l. Thus, applicant as of this writing estimates the clinical dosage of this compound to be within the range of 0.8 to 2.0 ⁇ g/eye, probably about 1.2 ⁇ g/eye.
  • the low dosage contemplated herein for these compounds as the isopropyl ester is below 0.2 ⁇ g/eye, to as low as 0.03 ⁇ g/eye.
  • these two isopropyl ester compounds are topically applied to the eye in a dosage of about 0.050 to below 5.0 ⁇ g/eye, or about 0.10 to 4.5 ⁇ g/eye, or about 0.50 to 2.5 ⁇ g/eye, or about 1.0 to 2.0 ⁇ g/eye.
  • the three isopropyl ester compounds disclosed herein before are topically applied in a dosage range of about 0.050 to 0.750 ⁇ g/eye, preferably about 0.075 to 0.250 ⁇ g/eye, more preferably about 0.100 to 0.175 ⁇ g/eye.
  • Another family of 15-keto prostaglandins which should be useful in the practice of the present invention are 15-oxo-17-phenyl-18,19,20-trinor PGF 2 ⁇ N-ethylanide and 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF 2 ⁇ N-ethylamide.
  • the low dosage contemplated herein for these compounds is below 15 ⁇ g/eye to as low as 0.05 ⁇ g/eye.
  • these two compounds are topically applied to the eye in a dosage of about 10 ⁇ g to 0.10 ⁇ g/eye, or about 8 ⁇ g to 0.50 ⁇ g/eye, or about 6 ⁇ g to 1 ⁇ g/eye.
  • a dosage of about 10 ⁇ g to 0.10 ⁇ g/eye, or about 8 ⁇ g to 0.50 ⁇ g/eye, or about 6 ⁇ g to 1 ⁇ g/eye See U.S. Pat. No. 5,352,708 and U.S. Pat. No. 6,037,364 for the corresponding 15-OH compound, 17-phenyl-18,19,20 trinor PGF 2 ⁇ N-ethylamide, which has a clinical (daily) dose (FDA approved dose) of one drop of a 0.030% solution.
  • the clinical dosage of this compound is not known by the applicant; however, with typical drop sizes of about 20 to 50 ⁇ l, most usually about 30 to 35 ⁇ l, the dosage is estimated at about 6 to 15 ⁇ g/eye, probably about 9 ⁇ g/eye.

Abstract

15-keto latanoprost and other 15-keto prostaglandin analogs are used as ocularly applied intraocular pressure reducing agents.

Description

  • This application is a Continuation-In-Part of U.S. application Ser. No. 09/734,692, filed Dec. 13, 2000, in turn a Continuation-in-Part of U.S. application Ser. No. 09/620,416, filed Jul. 20, 2000.[0001]
    • BACKGROUND OF THE INVENTION
  • The prior art describes the use of prostaglandin analogs containing a ring structure in the omega chain for reducing intraocular pressure. A representative patent in this area is U.S. Pat. No. 5,321,128 to Stjernschantz. These compounds contain a hydroxy group or keto group as a substituent at the 15-position. Also, one subset of these compounds contains an unsubstituted phenyl group substituted on carbon atom number 17 of the omega chain and the absence of carbons 18-20. These types of structures, where the conventional prostaglandin carbons 18-20 and their equivalent are absent are named by Stjernschantz as 18,19,20-trinor prostaglandins. [0002]
  • One of the above-described type of compounds, latanoprost, is now sold commercially as an IOP (intraocular pressure) reducing eye drop. The clinical dosage is 1.5 μg per dose as an eye drop, once a day. This is the U.S. FDA approved dosage. The provided liquid composition product can contain 0.005% latanoprost used at a dosage of one drop, or about 30 μl, providing 1.5 μg per dose. Latanoprost is named by Stjernschantz as 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF[0003] 2α isopropyl ester.
  • Another compound of this family known to date is 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF[0004] 2α isopropyl ester, hereinafter referred to as 15-keto latanoprost.
  • The above noted patent describes a wide potential dosage range as therapeutically active. For example, see [0005] column 5, lines 33-66 of the '128 patent (“The composition contains about 0.1-30 μg, especially 1-10 μg, per application of the active substance . . . ”) Even so, the lowest dosage used in the '128 patent for any test compound for evaluating IOP reduction in humans or monkeys is 1.0 μg per eye. For 15-keto latanoprost in the '128 patent, the tested dosage in healthy human volunteers is 5 μg per eye and is 3 μg in the monkey eye. Latanoprost is tested in the '128 patent at a dosage of 1.0 μg per eye in healthy human volunteers and at a dosage of 10.4 μg in the monkey eye.
  • Latanoprost at its clinical concentration can cause pigmentation of the iris, a mild IOP spike and/or mild hyperemia. [0006]
    • SUMMARY OF THE INVENTION
  • It has been discovered that 15-keto latanoprost can be used in an unusually low dosage for reduction of IOP. Another embodiment of the present invention is the use of 15-keto latanoprost at a dosage up to about the clinical dosage of latanoprost. 15-keto latanoprost does not cause iridic pigmentation, an initial IOP spike nor any hyperemia at the dosages described herein. Still another embodiment of the present invention is the use of 15-keto latanoprost for maintaining IOP reduction over an extended time following an initial rapid IOP reduction bought about by another IOP reducing agent, such as latanoprost. [0007]
  • The embodiments of the present invention involve treatment of glaucoma where IOP reduction is needed and the lowering of IOP for purposes other than treatment of glaucoma. [0008]
  • This application describes other 15-keto prostaglandins useable at low dosages for treating ocular hypertension and glaucoma.[0009]
    • DESCRIPTION OF THE DRAWING
  • FIGS. 1 and 2 set forth the results of Example 1 comparing the employment of a dose of 0.175 μg latanoprost (FIG. 1) and the same dose of 15-keto latanoprost (FIG. 2) in the monkey eye. [0010]
  • FIG. 3 is a graph depicting a comparison of the results for the active ingredients of Example 1 without the controls, as depicted in FIGS. 1 and 2. [0011]
  • FIG. 4 depicts the results of Example 2 where an additional instillation of a small amount of latanoprost or 15-keto lantanoprost is administered 12 hours after instillation of a clinical dose of latanoprost in the monkey eye.[0012]
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to the employment of varying, including small, ocular dosages of 15-keto latanoprost, and related 15-keto compounds, as an IOP reducing agent, administered topically to the eye in the treatment of glaucoma or ocular hypertension. The active agent is administered as a topically applied ocular composition, most usually in the form of a liquid eye drop. [0013]
  • The dose of 15-keto latanoprost is selected so that any side effects caused by the ocular application of prostaglandin analogs, including those which contain a ring such as latanoprost, are substantially completely eliminated. The effective dose exemplified herein can be as low as about one-tenth the clinical dose of latanoprost. [0014]
  • The ophthalmic vehicle employed in the practice of the present invention is that now know in the art for IOP reducing agents, such as the a-fore-mentioned latanoprost and Rescula®, the latter which has an extended omega chain providing a docosanoid classification. Additional information on ophthalmic vehicles is found in the patent noted in the background section of this patent application. Although 15-keto latanoprost is an isopropyl ester, it is contemplated that the free acid as well as pharmaceutically acceptable salts, ethers and other esters are potentially useful in the practice of the present invention, such as those described in the above-noted patent. [0015]
  • As noted above, the clinical dose for latanoprost is about 1.5 μg per eye. At one-tenth the clinical dose, latanoprost is essentially inactive. Quite surprisingly, 15-keto latanoprost is an effective IOP reducing agent when used at about one tenth the clinical dose of latanoprost. It is contemplated in one embodiment of the present invention that the dosage range for 15-keto latanoprost as a topically applied ocular IOP reducing agent is about 0.100 to 0.750 μg/eye, preferably about 0.125 to 0.250 μg/eye, more preferably about 0.150 to 0.175 μg/eye. In another embodiment of the present invention, the dosage range for 15-keto latanoprost as a topically applied ocular IOP reducing agent is about 0.050 to below 5.0 μg/eye, or about 0.10 to 4.5 μg/eye, or about 0.50 to 2.5 μg/eye, or about 1.0 to 2.0 μg/eye. [0016]
    • EXAMPLE 1
  • This Example is an IOP test using the monkey eye in which about one tenth the clinical dose of latanoprost is compared in IOP reduction with the same dose of 15-keto latanoprost. [0017]
    • SUMMARY
  • The intraocular pressure lowering effects of the 0.0005% solution of 13,14-dihydro-15-keto-17-phenyl-18,19,20-trinor-PGF[0018] 2α-isopropyl ester (15-keto-latanoprost) and the 0.0005% solution of 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF2α-isopropyl ester (latanoprost) were compared following a single, topical ocular instillation in monkeys.
  • No intraocular pressure lowering effect was noted following the instillation of 0.0005% latanoprost. On the other hand, the instillation of 0.0005% 15-keto-latanoprost lowered the intraocular pressure by 2.4 [0019] mmHg 8 hours after the administration as compared with the pre-treatment value. The reduction in the intraocular pressure by the instillation of 15-keto-latanoprost was statistically significant as compared with that by the instillation of the vehicle (contralateral eye) or of 0.0005% latanoprost.
  • These results indicate that 15-keto-latanoprost exerts a potent intraocular pressure lowering effect with a minute dose, and suggest that 13,14-dihydro-15-keto-17-phenyl-18,19,20-trinor- PGF[0020] 2α (15-keto acid of latanoprost) itself produced as a metabolite from latanoprost in the eyes participates in the reduction in the intraocular pressure after the instillation of latanoprost.
    • Materials and Methods
  • 1. Test Substance [0021]
  • 13,14-dihydro-15-keto-17-phenyl-18,19,20-trinor-PGF[0022] 2α-isopropyl ester (15-keto-latanoprost)
  • 13,14-dihydro-17-phenyl-18,19,20-trinor- PGF[0023] 2α-isopropyl ester (latanoprost,)
  • 2. Preparation of Dosing Solutions [0024]
  • The solution containing 15-keto-latanoprost or latanoprost at 0.0005% was prepared with the following vehicle. Composition of the vehicle[0025] 1) (/mL): NaCl (4.1 mg), NaH2PO4-H2O (4.6 mg), Na2HPO4-2H2O (5.94 mg), Benzalkonium Chloride (0.2 mg) and water for injection
  • 3. Animals [0026]
  • Five male cynomolgus monkeys purchased from Kasyo Co., Ltd. were used. These monkeys were housed individually in cages for monkeys in a room which was maintained at room temperature of 24±1° C., relative humidity of 55±10%, ventilation rate of about 12 times/hour and 12-hour light-dark cycle (fluorescent lighting: 8:00 a.m. to 8:00 p.m.). The animals were given food pellets for monkeys (PS, Oriental Yeast Co., Ltd.), vegetables and fruits, and allowed free access to tap water from an automatic dispenser. The healthy animals without abnormalities in the anterior segment of the eye were used in this study. [0027]
  • 4. Test Groups and Administration Method [0028]
    Administration Volume of
    Group method administration n
    15-keto-latanoprost Instillation 35 μL/eye 5
    0.0005%
    Latanoprost Instillation 35 μL/eye 5
    0.0005%
  • Five monkeys were divided into 2 groups of the group 1 (3 monkeys) and group 2 (2 monkeys). The 0.0005% 15-keto-latanoprost and 0.0005% latanoprost were instilled into the right eye of monkeys in the [0029] group 1 and 2, respectively. One week later, 0.0005% latanoprost and 0.0005% 15-keto-latanoprost were instilled into the right eye of monkeys in the group 1 and 2, respectively, in a crossover way. Thirty-five μL of each test solution was administered by use of a micropipet (Pipetman P 100, Gilson). To the left eye the same volume of the vehicle was administered. The intraocular pressure in each group before the instillation was as follows (in mmHg, mean±S.E.): the group receiving 15-keto-latanoprost; the right eye: 16.6±0.5, the left eye: 16.6±0.2, the group receiving latanoprost; the right eye: 15.8±0.7, the left eye: 17.0±0.3. There were no statistically significant differences between the values of the intraocular pressure before the instillation (Student's t-test).
  • 5. Measurement of Intraocular Pressure [0030]
  • The animals were systemically anesthetized by an intramuscular injection of 5 mg/kg of ketamine hydrochloride (Ketalar®50, Sankyo Co., Ltd.), and the interior segment of both eyes was anesthetized by a instillation of 0.4% oxybuprocaine hydrochloride (Benoxil® 0.4% solution, Santen Pharmaceutical Co., Ltd.). The animals were fixed in a sitting position, and the intraocular pressure was measured by use of an applanation pneumatonograph (Alcon Japan Ltd.) before, and 2, 4, 8, 12 and 24 hours after the instillation. The animals were kept in cages excepting the time of measurement of the intraocular pressure. [0031]
  • 6. Statistical Analysis [0032]
  • The data were statistically analyzed with Student's t-test. P values less than 0.05 were considered to be statistically significant. [0033]
    • Results
  • The instillation of 0.0005% latanoprost did not lower the intraocular pressure (FIG. 1). On the contrary, the intraocular pressure in 0.0005% 15-keto-latanoprost-treated eye was lowered by 2.4 mmHg 8 hours after the instillation as compared with the pre-treatment value, and the reduction in the intraocular pressure was statistically significant as compared with that in the vehicle-treated contralateral eye (FIG. 2). In addition, as shown in FIG. 3, the reduction in the intraocular pressure with 0.0005% 15-keto-latanoprost was also statistically significant as compared with 0.0005% latanoprost. [0034]
    • Discussion
  • In the present study, the intraocular pressure lowering effects of latanoprost and 15-keto-latanoprost in monkeys were compared following a single instillation at 0.0005%, for about one-tenth the amount of clinically used latanoprost. While no reduction in the intraocular pressure was noted following the instillation of 0.0005% latanoprost, the instillation of 0.0005% 15-keto-latanoprost significantly lowered the intraocular pressure. [0035]
  • Above results clearly indicate that the potency of intraocular pressure lowering effect of 15-keto-latanoprost is significantly greater than that of latanoprost. Furthermore, the fact that 15-keto-latanoprost exerted a significant intraocular pressure lowering effect at such a low concentration, at which latanoprost had no effect, strongly suggests that 15-keto acid of latanoprost, a 13,14-dihydro-15-keto-type metabolite produced from latanoprost in the eyes, participates in the intraocular pressure lowering effect after the instillation of latanoprost. [0036]
    • References EXAMPLE 2
  • This Example illustrates the employment of a low dose of 15-keto latanoprost for maintaining a low IOP level following single administration of another IOP reducing agent for obtaining a rapid drop in IOP. [0037]
    • Summary
  • The intraocular pressure in monkeys after single instillation of 0.005% latanoprost (clinical concentration) showed the maximum reduction at 12 hours after the instillation and thereafter the intraocular pressure recovered gradually and returned to the predosing level at 24 hours after the instillation. No difference was found between changes in intraocular pressure after additional instillation of 0.0005% latanoprost (the concentration: {fraction (1/10)} of latanoprost 0.005%) at 12 hours after instillation of 0.005% latanoprost and those after single instillation of 0.005% latanoprost. On the other hand, when 0.0005% 15-keto-latanoprost was additionally instilled at 12 hours after instillation of 0.005% latanoprost, the intraocular pressure was significantly maintained continuously at low levels as compared with that when 0.005% latanoprost alone was instilled or that when 0.0005% latanoprost was instilled additionally at 12 hours after instillation of 0.005% latanoprost. These results suggest that 15-keto acid of latanoprost, a 13,14-dihydro-15-keto type metabolite, produced from latanoprost in the eye after instillation of latanoprost participates in the maintenance of the intraocular pressure lowering effect after instillation of latanoprost. [0038]
    • I. Introduction
  • In the present study, the animals were treated by the instillation with latanoprost at the clinical concentration alone, or additional instillation of a small amount of latanoprost or 15-keto-[0039] latanoprost 12 hours after instillation of latanoprost when the IOP showed the maximum reduction after instillation of latanoprost. The changes of IOP in 3 different treatment groups were compared to investigate the significance of the presence of 15-keto acid of latanoprost, a 13,14-dihydro-15-keto type metabolite, in maintaining the IOP lowering effect observed after instillation of latanoprost.
    • II. Materials and Methods
  • 1. Test substance [0040]
  • 15-keto-latanoprost and latanoprost which were synthesized in Ueno Institute for Medical Science were used. [0041]
  • 2. Animals [0042]
  • Six male cynomolgus monkeys (body weight: 3.2-3.8 μg) were used. These monkeys were housed individually in cages for monkeys in a monkey rearing room which was maintained at room temperature of 24±1° C., relative humidity of 55±10%, and ventilation of about 12 times/hour and a 12-hour light-dark cycle (fluorescent lighting: 8:00 a.m. to 8:00 p.m.). The animals were given solid food for monkeys (PS, Oriental Yeast Co., Ltd.), vegetables and fruits, and allowed free access to tap water from an automatic dispenser. The healthy animals without abnormalities in the anterior segment were used in this study. [0043]
  • 3. Preparation of Dosing Solution [0044]
  • 0.0005% and 0.005% latanoprost eye drops and 0.0005% 15-keto-latanoprost eye drops were prepared with a vehicle consisting of the following composition. The composition of the vehicles in 1 mL was as follows: sodium chloride (4.1 mg), sodium hydrogenphosphate-1H[0045] 2O (4.6 mg), disodium hydrogenphosphate-2H2O (5.94 mg), benzalkonium chloride (0.200 mg) and water for injection (1 mL).
  • 4. Administration Method of Test Substance [0046]
  • In the present study, changes in IOP after instillation of 0.005% latanoprost alone at the clinical concentration were compared with those in IOP after additional instillation of 0.0005% latanoprost or 0.0005% 15-keto-[0047] latanoprost 12 hours after instillation of 0.005% latanoprost to investigate the significance of the presence of a 13,14-dihydro-15-keto type metabolite in maintaining the IOP lowering effect observed after instillation of latanoprost.
  • The following 3 treatments were given to the right eye of monkeys at the intervals of at least 10 days. Namely, (1) instillation of 0.005% latanoprost alone, (2) additional instillation of 0.0005% latanoprost at 12 hours after instillation of 0.005% latanoprost, and (3) additional instillation of 0.0005% 15-keto-latanoprost at 12 hours after instillation of 0.005% latanoprost. Thirty [L of each test substance was instilled into the right eye of animals with a Pipetman (Gilson). The same amount of the vehicle was instilled into the left eye. [0048]
  • 5. Measurement of IOP [0049]
  • After the ocular surface of monkeys was anesthetized with 0.4% oxybuprocaine hydrochloride (Benoxil® 0.4% solution, Santen Pharmaceutical Co., Ltd.) under i.m. systemic anesthesia with 5-7.5 mg/kg of ketamine hydrochloride, IOP was measured with an applanation pneumatonograph (Alcon Japan Ltd.). IOP was measured before instillation and at 4, 8, 12, 16, 20, 24, 28 and 32 hours after instillation of 0.005% latanoprost. [0050]
    • III. Results
  • As FIG. 4 shows, when 0.005% latanoprost alone was instilled into the eye of monkeys, IOP decreased with time at 4, 8 and 12 hours after instillation. The IOP returned with time toward the predosing levels at 16 and 20 hours after instillation of 0.005% latanoprost. IOP returned toward the predosing levels at 24 hours after instillation. [0051]
  • Additional instillation of 0.0005% latanoprost at 12 hours after instillation of 0.005% latanoprost did not affect IOP as compared with that after instillation of 0.005% latanoprost alone. [0052]
  • On the other hand, the IOP was maintained at significantly low levels when 0.0005% 15-keto-latanoprost was additionally instilled at 12 hours after instillation of 0.005% latanoprost as compared with that when 0.005% latanoprost alone was instilled, or that when 0.0005% latanoprost was additionally instilled 12 hours after instillation of 0.005% latanoprost. [0053]
  • These results indicate that the IOP lowering effect after instillation of latanoprost is prolonged markedly by additional instillation of a small amount of 15-keto-latanoprost. [0054]
  • Other 15-keto prostaglandins which should be useful in the practice of the present invention are 15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF[0055] 2α and 13,14-dihydro-15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF2α isopropyl esters. The corresponding pharmaceutically acceptable salts, ethers, other esters and amides should be useful in the practice of the present invention. See U.S. Pat. No. 5,510,383 for the corresponding 15-OH compound. The clinical (once a day) dosage (FDA approved dosage) for 16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF2α isopropyl ester is one drop of a 0.004% solution. Drop size can range from about 20 to 50 μl, typically about 30 to 35 μl. Thus, applicant as of this writing estimates the clinical dosage of this compound to be within the range of 0.8 to 2.0 μg/eye, probably about 1.2 μg/eye. The low dosage contemplated herein for these compounds as the isopropyl ester is below 0.2 μg/eye, to as low as 0.03 μg/eye. In another embodiment of this invention, these two isopropyl ester compounds are topically applied to the eye in a dosage of about 0.050 to below 5.0 μg/eye, or about 0.10 to 4.5 μg/eye, or about 0.50 to 2.5 μg/eye, or about 1.0 to 2.0 μg/eye. In still another embodiment of this invention, the three isopropyl ester compounds disclosed herein before are topically applied in a dosage range of about 0.050 to 0.750 μg/eye, preferably about 0.075 to 0.250 μg/eye, more preferably about 0.100 to 0.175 μg/eye.
  • Another family of 15-keto prostaglandins which should be useful in the practice of the present invention are 15-oxo-17-phenyl-18,19,20-trinor PGF[0056] 2α N-ethylanide and 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF2α N-ethylamide. The low dosage contemplated herein for these compounds is below 15 μg/eye to as low as 0.05 μg/eye. In another embodiment of this invention, these two compounds are topically applied to the eye in a dosage of about 10 μg to 0.10 μg/eye, or about 8 μg to 0.50 μg/eye, or about 6 μg to 1 μg/eye. See U.S. Pat. No. 5,352,708 and U.S. Pat. No. 6,037,364 for the corresponding 15-OH compound, 17-phenyl-18,19,20 trinor PGF2α N-ethylamide, which has a clinical (daily) dose (FDA approved dose) of one drop of a 0.030% solution. As of this writing the clinical dosage of this compound is not known by the applicant; however, with typical drop sizes of about 20 to 50 μl, most usually about 30 to 35 μl, the dosage is estimated at about 6 to 15 μg/eye, probably about 9 μg/eye.
  • Variations of the present invention will be apparent to the skilled artisan. For example, when 15-keto latanoprost or another 15-keto compound described herein is used in a low dose maintenance regimen, the initial rapid IOP reduction can be obtained with known IOP reducing agents other than latanoprost, for example, Rescula®, Timolol, Alphagan, Azopt, Cosopt, Travoprost (isopropyl ester of fluprostenol), Bimatoprost and so on can be employed. Another alternative is to initially use a higher dose of 15-keto latanoprost, or of one of the other 15-keto compounds described herein. The dosages disclosed herein are for human use. [0057]

Claims (46)

We claim:
1. A method for reducing intraocular pressure or for treating glaucoma which comprises topically applying to a mammal as an ocular eye drop a compound selected from the group consisting of 15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF2α isopropyl ester, 13,14-dihydro-15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF2α isopropyl ester and 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF2α isopropyl ester in a dose below the known dose for the corresponding 15-OH compound.
2. The method of claim 1 wherein the compound administered is 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF2α isopropyl ester.
3. The method of claim 1 wherein the dose is about 0.05 to 0.750 μg per eye.
4. The method of claim 3 wherein the dose is about 0.075 to 0.250 μg per eye.
5. The method of claim 4 wherein the dose is about 0.100 to below 0.175 μg per eye.
6. A method for reducing intraocular pressure or for treating glaucoma which comprising topically applying to a mammal as an ocular eye drop a compound selected from the group consisting of 15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF2α isopropyl ester, 13,14-dihydro-15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF2α isopropyl ester and 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF2α isopropyl ester in a dose of about 0.050 to below 5.0 μg per eye.
7. The method of claim 6 wherein the compound administered is 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF2α isopropyl ester.
8. The method of claim 6 wherein the dose is about 0.10 to 4.5 μg per eye.
9. The method of claim 8 wherein the dose is about 0.50 to 2.5 μg per eye.
10. The method of claim 9 wherein the dose is about 1.0 to 2.0 μg per eye.
11. The method of claim 1 or claim 6 wherein the compound is applied one or two times a day.
12. The method of claim 1 or claim 6 wherein the dose is about one-tenth the usual dose of the corresponding 15-OH compound.
13. The method of claim 2 or claim 7 wherein the dose is about one-tenth the usual dose of latanoprost.
14. The method of claim 1 or claim 6 wherein the mammal is a human.
15. The method for maintaining a reduced intraocular pressure by periodic administration to a mammal as a topically applied ocular eye drop, an effective amount of a compound selected from the group consisting of 15-oxo-16-(3-trifluofomethyl phenoxy)-17,18,19,20-tetranor PGF2α isopropyl ester, 13,14-dihydro-15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF2α isopropyl ester and 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF2α isopropyl ester.
16. A method of claim 15 wherein the compound administerd is 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF2α isopropyl ester.
17. The method of claim 15 wherein the dose is about 0.050 to 0.750 μg per eye.
18. The method of claim 17 wherein the dose is about 0.075 to 0.250 μg per eye.
19. The method of claim 18 wherein the dose is about 0.100 to 0.175 μg per eye.
20. The method of claim 15 wherein the dose is about 0.050 to below 5.0 μg per eye.
21. The method of claim 20 wherein the dose is about 0.10 to 4.50 μg per eye.
22. The method of claim 21 wherein the dose is about 0.50 to 2.5 μg per eye.
23. The method of claim 22 wherein the dose is about 1.0 to 2.0 μg per eye.
24. The method of claim 15 wherein the compound is applied one or two times a day.
25. The method of claim 15 wherein intraocular pressure is initially reduced by application of a 15-OH compound.
26. The method of claim 25 wherein intraocular pressure is initially reduced by application of latanoprost.
27. The method of claim 15 wherein the mammal is a human.
28. A method for reducing intraocular pressure or for treating glaucoma which comprises topically applying to a mammal as an ocular eye drop a compound selected from the group consisting of 15-oxo-17-phenyl-18,19,20 trinor PGF2α N-ethylamide and 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF2α N-ethylamide.
29. The method of claim 28 wherein the dose is about one-tenth the usual dose of the corresponding 15-OH compound.
30. The method of claim 28 wherein the mammal is a human.
31. The method for maintaining a reduced intraocular pressure by periodic administration to a mammal as a topically applied ocular eye drop, an effective amount of a compound selected from the group consisting of 15-oxo-17-phenyl-18,19,20 trinor PGF2α N-ethylamide and 13,14-dihydro-15-oxo-17-phenyl-18,19,20-trinor PGF2α N-ethylamide.
32. The method of claim 31, wherein the compound is applied one or two times a day.
33. The method of claim 28 wherein the dose is about 0.05 to 15μg per eye.
34. The method of claim 33 wherein the dose is about 0.10 to 10 μg per eye.
35. The method of claim 34 wherein the dose is is about 0.50 to 8.0 μg per eye.
36. The method of claim 35 wherein the dose is about 1.0 to 6.0 μg per eye.
37. The method of claim 31 wherein the dose is about 0.05 to 15 μg per eye.
38. The method of claim 37 wherein the dose is about 0.10 to 10 μg per eye.
39. The method of claim 38 wherein the dose is about 0.50 to 8.0 μg per eye.
40. The method of claim 39 wherein the dose is about 1.0 to 6.0 μg per eye.
41. The method of claim 31 wherein the compound is applied one or two times a day.
42. The method of claim 31 wherein the intraocular pressure is initially reduced by application of a 15-OH compound.
43. The method of claim 31 wherein the mammal is a human.
44. The method of claim 1 wherein the compound administered is 15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF2α isopropyl ester or 13,14-dihydro-15-oxo-16-(trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF2α isopropyl ester.
45. The method of claim 6 wherein the compound administered is 15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF2α isopropyl ester or 13,14-dihydro-15-oxo-16-(trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF2α isopropyl ester.
46. The method of claim 15 wherein the compound administered is 15-oxo-16-(3-trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF2α isopropyl ester or 13,14-dihydro-15-oxo-16-(trifluoromethyl phenoxy)-17,18,19,20-tetranor PGF2α isopropyl ester.
US10/385,621 2000-07-20 2003-03-12 Treatment of ocular hypertension and glaucoma Abandoned US20030220395A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/385,621 US20030220395A1 (en) 2000-07-20 2003-03-12 Treatment of ocular hypertension and glaucoma

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62041600A 2000-07-20 2000-07-20
US09/734,692 US20020035148A1 (en) 2000-07-20 2000-12-13 Treatment of ocular hypertension
US09/851,111 US6596765B2 (en) 2000-07-20 2001-05-09 Treatment of ocular hypertension and glaucoma
US10/385,621 US20030220395A1 (en) 2000-07-20 2003-03-12 Treatment of ocular hypertension and glaucoma

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/851,111 Division US6596765B2 (en) 2000-07-20 2001-05-09 Treatment of ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
US20030220395A1 true US20030220395A1 (en) 2003-11-27

Family

ID=27088716

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/734,692 Abandoned US20020035148A1 (en) 2000-07-20 2000-12-13 Treatment of ocular hypertension
US09/851,111 Expired - Fee Related US6596765B2 (en) 2000-07-20 2001-05-09 Treatment of ocular hypertension and glaucoma
US10/385,621 Abandoned US20030220395A1 (en) 2000-07-20 2003-03-12 Treatment of ocular hypertension and glaucoma

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/734,692 Abandoned US20020035148A1 (en) 2000-07-20 2000-12-13 Treatment of ocular hypertension
US09/851,111 Expired - Fee Related US6596765B2 (en) 2000-07-20 2001-05-09 Treatment of ocular hypertension and glaucoma

Country Status (7)

Country Link
US (3) US20020035148A1 (en)
EP (1) EP1317269A2 (en)
JP (1) JP2004504350A (en)
KR (1) KR20030016418A (en)
AU (1) AU2001272738A1 (en)
CA (1) CA2416681A1 (en)
WO (1) WO2002007731A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713268B2 (en) * 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
WO2003011299A2 (en) * 2001-07-31 2003-02-13 Sucampo Ag Treatment of ocular hypertension and glaucoma
US20040254247A1 (en) * 2001-07-31 2004-12-16 Ryuji Ueno Method and composition for treatnment of ocular hypertension and glaucoma
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
JP2004521960A (en) * 2001-08-23 2004-07-22 スキャンポ・アーゲー Methods and compositions for the treatment of ocular hypertension and glaucoma
US20060264353A1 (en) * 2002-03-21 2006-11-23 Maxey Kirk M Prostaglandin f2alpha analogs and their use in combination with antimicrobial proteins for the treatment of glaucoma and intraocular hypertension
JP2005519978A (en) * 2002-03-28 2005-07-07 スキャンポ・アーゲー Methods for treating ocular hypertension and glaucoma
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
US20040225014A1 (en) * 2003-02-14 2004-11-11 Sucampo Ag Method for treating ocular hypertension and glaucoma
WO2010102078A1 (en) 2009-03-04 2010-09-10 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
WO2007066479A1 (en) * 2005-11-16 2007-06-14 Mitsubishi Gas Chemical Company, Inc. Method for determination of amount of double-stranded dna and kit for the determination
WO2009116098A1 (en) 2008-03-19 2009-09-24 Ciro Caruso Composition for stimulating the growth of eyelashes, eyebrows and hairs
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
TWI680975B (en) 2018-06-26 2020-01-01 奇鈦科技股份有限公司 Uv absorbing compound and applications thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5422368A (en) * 1988-09-06 1995-06-06 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3876050T2 (en) * 1987-09-18 1993-03-25 R Tech Ueno Ltd OCULAR HYPOTENSIVAGENTS.
EP0366279B1 (en) * 1988-10-01 1994-09-21 R-Tech Ueno Ltd. Ocular hypotensive agents
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
CN1133466C (en) * 1998-04-07 2004-01-07 阿尔康实验室公司 Gelling ophthalmic composition containing xanthan gum
HUP0300391A3 (en) * 2000-03-16 2008-05-28 Sucampo Ag Use of prostaglandin related compounds for preparation of composition for use in treatment of ocular hypertension and glaucoma

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5422368A (en) * 1988-09-06 1995-06-06 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5422369A (en) * 1988-09-06 1995-06-06 Kabi Pharmacia Ab Prostaglanddin derivatives for the treatment of glaucoma or ocular hypertension
US5578618A (en) * 1988-09-06 1996-11-26 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5627208A (en) * 1988-09-06 1997-05-06 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5849791A (en) * 1988-09-06 1998-12-15 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6030999A (en) * 1988-09-06 2000-02-29 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension

Also Published As

Publication number Publication date
EP1317269A2 (en) 2003-06-11
WO2002007731A2 (en) 2002-01-31
US6596765B2 (en) 2003-07-22
US20020035148A1 (en) 2002-03-21
US20020035149A1 (en) 2002-03-21
KR20030016418A (en) 2003-02-26
JP2004504350A (en) 2004-02-12
AU2001272738A1 (en) 2002-02-05
WO2002007731A3 (en) 2003-04-03
CA2416681A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
US10045997B2 (en) Hypotensive lipid and timolol compositions and methods of using same
US6596765B2 (en) Treatment of ocular hypertension and glaucoma
US5510383A (en) Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6646001B2 (en) Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
EP1541151B1 (en) REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
US6344478B2 (en) Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US6342524B1 (en) Use of non-steroidal anti-inflammatory agents in combination with compounds that have FP prostaglandin agonist activity to treat glaucoma and ocular hypertension
Hellberg et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist
AU2002312221A1 (en) Hypotensive lipid (prostaglandin derivatives) and timolol compositions and methods of using same
US6166073A (en) Combinations of DP and FP type prostaglandins for lowering IOP
US6329426B1 (en) Method for treating ocular hypertension of glaucoma
Kashiwagi et al. Metabolites of isopropyl unoprostone as potential ophthalmic solutions to reduce intraocular pressure in pigmented rabbits
US5627209A (en) Use of certain 9-haloprostaglandins to treat glaucoma and ocular hypertension
US20050043412A1 (en) Remedies for glaucoma comprising bunazosin and prostaglandins
EP1142576B1 (en) Drug compositions for the treatment of ocular hypertension or glaucoma
AU2010202674B2 (en) Hypotensive lipid and timolol compositions and methods of using same
JP2010070577A (en) Pharmaceutical composition for treating ocular hypertension or glaucoma
AU2014201651A1 (en) Hypotensive lipid and timolol compositions and methods of using same

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION